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It is now well established that significant interindividual variability
exists in the disposition and pharmacologic effects of certain med-
ications. Influences such as environmental exposures, nutritional
status, co-morbidities, severity of disease, and concomitant med-
ications have all been associated with heterogeneity in drug
responses. In addition, the profound contribution of genetics has
been appreciated for some time and is receiving greater emphasis
in recent years.
Approximately 1.8 million single nucleotide polymorphisms
(SNPs) in the human genome have been identified by The SNP
Consortium (http://snp.cshl.org), a collaboration of several compa-
nies and institutions. Numerous SNPs in genes encoding various
drug-metabolizing enzymes, drug transporters, and drug targets
(e.g., receptors, enzymes involved in metabolism of endogenous
substrates, etc.) have been shown to be associated with interindi-
vidual differences in the pharmacokinetics and pharmacodynamics
of certain medications (Evans and McLeod 2003). Many in vitro
and in vivo “pharmacogenetic” studies performed to date have eval-
uated the association between SNPs in a single gene and a specific
drug’s pharmacologic properties. Preclinical and clinical investiga-
tions have evaluated genetic determinants of drug metabolism and
demonstrated that polymorphisms in genes encoding drug-metabo-
lizing enzymes can markedly influence a drug’s pharmacokinetics,
change its efficacy and/or toxicity profile, and necessitate dosing
changes in certain individuals. More recent studies have begun to
evaluate the association between drug target polymorphisms and
pharmacodynamic effects. Three well-documented “pharmacoge-
netic” examples are outlined in Table 1. 
Because of the complex interplay between the pharmacologic
effects of drugs and disease pathophysiology, inherited differences in
drug responses are most likely polygenic rather than monogenic in
nature (Evans and McLeod 2003). Hence, “pharmacogenomics” has
emerged as a new field of study that attempts to identify and eluci-
date the contribution of multiple interrelated genes to the efficacy
and toxicity of certain medications. Ultimately, the goal of pharma-
cogenomics is to account for and minimize interindividual variabili-
ty in drug response, thus allowing clinicians to enhance the efficacy
and minimize the toxicities associated with drug therapy. By consid-
ering the role of multiple genes, the field of pharmacogenomics
seeks to divide a
given patient popula-
tion into smaller, less
variable, more pre-
dictable subgroups,
which enables clini-
cians to individualize
drug therapy (i.e., to
administer the right drug, at the right dose, to the right patient)
(Roses 2000).
For example, it is now recognized that SNPs can affect the
activity of drug transporters and drug-metabolizing enzymes and
can substantially influence an individual’s systemic exposure to cer-
tain agents. Genetic variation in the target of a given drug can also
contribute to its pharmacologic effect. Moreover, variation in a dis-
ease-modifying gene can affect the rate and/or extent of disease
progression, ultimately influencing the therapeutic effect of a drug.
Therefore, simultaneously characterizing genetic determinants of
drug exposure, drug effect, and disease progression will likely
improve our ability to predict the overall effect of a drug in an
individual patient. In other words, genomic data will divide a given
patient population into subpopulations of “responders” and “non-
responders,” allowing prescribers to better predict the potential
therapeutic effect of a drug. Pharmacogenomic testing may also
lead to more predictable toxicity profiling for individual patients,
thus prospectively identifying and eventually minimizing idiosyn-
cratic or unexpected drug reactions. Such testing might also offer
new insight into the mechanisms of such toxicities. Overall, this
approach has the potential to account for variability in drug
response, maximize beneficial and minimize untoward drug effects,
optimize therapeutic decision making, and ultimately improve
clinical outcomes.
To facilitate utilization of pharmacogenomic-guided therapy,
genomic diagnostics are also being developed at a rapid rate.
Microarray and “chip” technologies have enabled the simultane-
ous evaluation of multiple SNPs in multiple genes. We envision
that a variety of diagnostic pharmacogenomic “packages” will be
developed for certain patient populations at risk for or recently
diagnosed with specific diseases (e.g. breast cancer, cardiovascular
disease, asthma). These packages will provide critical genomic
information that will help clinicians predict disease susceptibility,
the likelihood of disease progression, drug efficacy, and drug toxi-
city. Together with other clinical information (e.g. breast cancer
stage, lipid profile, lung function studies), the genomic data will
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Table 1. Examples of genetic predictors of drug response.
Gene target SNP Affected drug Clinical implication
Thiopurine methyltransferase TPMT*2, *3A, *3C Mercaptopurine/azathioprine Increased toxicity (hematopoietic)
(Krynetski et al. 1996)
CYP2C19  CYP2C19*2, *3 Omeprazole Enhanced efficacy (ulcer cure rates)
(Furuta et al. 1998)
β2-Adrenergic receptor Arg16Gly Albuterol Increased tolerance (receptor 
(Lima et al. 1999)  desensitization and reduced 
bronchodilation)
Darryl C. Zeldinsubstantially improve a clinician’s ability to identify subpopula-
tions of patients most likely to respond to specific preventive or
therapeutic strategies, as well as the ability to identify specific
drugs and dosing regimens that can be used in individual patients
to optimize outcomes. In addition, pharmacogenomic concepts
will be applied to the development of novel therapeutic agents by
the pharmaceutical industry, which has already reported substan-
tial increases in the use of pharmacogenomic testing in clinical tri-
als (Roses 2000). This approach will eventually yield medicines
that will directly modify genetically validated targets.
The future of pharmacogenomics is quickly becoming a reali-
ty. Indeed, preclinical and clinical investigations are already evalu-
ating the contribution of multiple genes to the observed variability
in drug response. However, unraveling the full potential of phar-
macogenomics will require the translation of discoveries from
basic to clinical science, and eventually the application of these
findings to patient care (i.e. from bench to bedside). Current
approaches to pharmacogenomic research involve SNP discovery,
in vitro studies that characterize the functional and mechanistic
significance of known SNPs, and in vivo studies that investigate
the clinical relevance of known SNPs in healthy volunteers or
patients. Clinical evaluations have included prospective clinical
pharmacology studies with pharmacokinetic and pharmacody-
namic end points and retrospective outcome analyses of genetic
subgroups from randomized controlled clinical trials. Prospective
clinical trials that evaluate the safety and efficacy of pharmacoge-
nomic-guided drug therapy will be necessary to determine if these
strategies can improve patient outcomes. Furthermore, detailed
economic analyses that evaluate the cost-effectiveness of such
approaches will be crucial before widespread implementation into
clinical practice can occur.
Understanding the relevance of genomic information will be
crucial to close the gap between basic science and patient care.
Moreover, open dialog regarding the numerous ethical issues sur-
rounding genomic testing, such as the protection of privacy as it
relates to insurance and employment, will be needed as this field
moves towards clinical application. Ultimately, the factors essential
to the appropriate utilization of pharmacogenomic data include
collaboration between basic researchers and clinicians, develop-
ment of a multidisciplinary approach to patient care, and educa-
tion of clinician–scientists in pharmacogenomic medicine. Perhaps
the biggest challenge to the effective use of pharmacogenomic
strategies in clinical practice involves educating the public on its
availability, uses, and limitations. 
The recent sequencing of the human genome has facilitated
identification of polymorphic variants in genes involved in the dis-
position and pharmacologic action of numerous drugs. The rapidly
growing field of pharmacogenomics offers enormous potential for
improving how clinicians use medications. Pharmacogenomics will
ultimately minimize variability in how patients respond to medica-
tions, thereby enabling clinicians to individualize therapy and
improve overall clinical outcome.
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